Spoken Alpha
WGSWW
GeneDx Holdings Corp.
Overview
GeneDx provides exome and genome sequencing tests for diagnosing rare and genetic diseases, primarily serving pediatric patients, geneticists, and other specialists through third-party payors and healthcare systems.
GeneDx Holdings Corp.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks WGSWW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.06 | $0.94 | +12.5% | -1.8% | -4.2% |
| Q4 FY2026 | $0.89 | $0.87 | +2.8% | +3.5% | +3.0% |
| Q3 FY2026 | $0.78 | $0.73 | +6.4% | -1.5% | -4.5% |
| Q2 FY2026 | $1.17 | $1.02 | +14.6% | -0.6% | -1.4% |
| Q1 FY2025 | $1.14 | $0.98 | +16.2% | +4.0% | +4.8% |
| Q4 FY2025 | $0.81 | $0.79 | +2.1% | +6.5% | +6.8% |
| Q3 FY2025 | $1.05 | $0.99 | +5.7% | +8.9% | +7.0% |
| Q2 FY2025 | $1.15 | $0.99 | +16.0% | +1.2% | +0.4% |
| Q1 FY2024 | $1.31 | $1.12 | +17.2% | +1.8% | +0.3% |
| Q4 FY2024 | $0.98 | $0.88 | +10.8% | +1.8% | -0.6% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Maintained2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Maintained2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Katherine StuelandCEO9 mo17 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last call held guidance Q3 FY2026
- Kevin FeeleyCFO9 mo16 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
- Bryan DechairoCOO4 mo2 callsCurrentSample
COO since 2026 • 1/2 beats (50%) • last guidance cut Q1 FY2026
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for WGSWW.
$ curl https://api.spokenalpha.com/v1/companies/WGSWWFAQ
Frequently asked about WGSWW
Where can I find GeneDx Holdings Corp.'s (WGSWW) earnings call transcripts?
Spoken Alpha indexes WGSWW's earnings call transcripts at https://spokenalpha.com/companies/WGSWW. Each call links to attributed speakers and parsed analyst Q&A. GeneDx Holdings Corp.'s own investor relations page is at https://ir.genedx.com/.